Multivariate analysis
| . | LS . | FN . | ||
|---|---|---|---|---|
| β-coefficient . | P . | β-coefficient . | P . | |
| All patients | ||||
| Sex | −0.01 | .91 | 0.18 | .03 |
| Initial diagnosis | 0.05 | .78 | 0.14 | .40 |
| Age at diagnosis | 0.06 | .57 | −0.005 | .96 |
| Follow-up | 0.04 | .69 | 0.06 | .56 |
| Corticotherapy | 0.19 | .23 | 0.14 | .35 |
| HSCT | 0.05 | .56 | −0.24 | .006 |
| Chemotherapy group | ||||
| Sex | −0.11 | .3 | 0.12 | .26 |
| Initial diagnosis | −0.06 | .58 | −0.04 | .67 |
| Age at diagnosis | −0.09 | .52 | −0.18 | .19 |
| Follow-up | 0.01 | .94 | 0.01 | .94 |
| CNS radiation | 0.001 | .99 | −0.06 | .62 |
| HSCT group | ||||
| Sex | 0.13 | .39 | 0.15 | .31 |
| Age at HSCT | 0.38 | .03 | 0.3 | .07 |
| Follow-up | 0.11 | .50 | 0.14 | .39 |
| TBI | 0.23 | .12 | 0.14 | .31 |
| Significant GVHD* | −0.11 | .41 | −0.15 | .25 |
| Hypogonadism | −0.17 | .30 | −0.32 | .04 |
| . | LS . | FN . | ||
|---|---|---|---|---|
| β-coefficient . | P . | β-coefficient . | P . | |
| All patients | ||||
| Sex | −0.01 | .91 | 0.18 | .03 |
| Initial diagnosis | 0.05 | .78 | 0.14 | .40 |
| Age at diagnosis | 0.06 | .57 | −0.005 | .96 |
| Follow-up | 0.04 | .69 | 0.06 | .56 |
| Corticotherapy | 0.19 | .23 | 0.14 | .35 |
| HSCT | 0.05 | .56 | −0.24 | .006 |
| Chemotherapy group | ||||
| Sex | −0.11 | .3 | 0.12 | .26 |
| Initial diagnosis | −0.06 | .58 | −0.04 | .67 |
| Age at diagnosis | −0.09 | .52 | −0.18 | .19 |
| Follow-up | 0.01 | .94 | 0.01 | .94 |
| CNS radiation | 0.001 | .99 | −0.06 | .62 |
| HSCT group | ||||
| Sex | 0.13 | .39 | 0.15 | .31 |
| Age at HSCT | 0.38 | .03 | 0.3 | .07 |
| Follow-up | 0.11 | .50 | 0.14 | .39 |
| TBI | 0.23 | .12 | 0.14 | .31 |
| Significant GVHD* | −0.11 | .41 | −0.15 | .25 |
| Hypogonadism | −0.17 | .30 | −0.32 | .04 |
Significant GVHD indicates acute GVHD grades II, III, or IV or chronic extensive GVHD.